Meeting
2016 ASCO Annual Meeting
Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Authors
Michael J. Morris
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
Michael J. Morris , Daniel Peter Petrylak , A. Oliver Sartor , Nicholas J. Vogelzang , Michael Groaning , Samuel Ejadi , Anthony W. Tolcher , Hani M. Babiker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02202447
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2586)
DOI
10.1200/JCO.2016.34.15_suppl.2586
Abstract #
2586
Poster Bd #
286
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Michael J. Morris
Poster
2018 ASCO Annual Meeting
A phase I study of 177Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).
First Author: Megan Crumbaker
Poster
2021 ASCO Annual Meeting
TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer.
First Author: Ben Buelow
Poster
2020 Genitourinary Cancers Symposium
Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer.
First Author: Carissa Chu